EU/3/10/807: Orphan designation for the treatment of frontotemporal dementia with parkinsonism-17
Table of contents
On 26 November 2010, orphan designation (EU/3/10/807) was granted by the European Commission to Dr Hans Moebius, United Kingdom, for methylthioninium for the treatment of frontotemporal dementia with parkinsonism-17.
The sponsorship was transferred to Prof. Claude Wischik, United Kingdom, in February 2012 and subsequently to TauRx Therapeutics Europe Ltd, United Kingdom, in August 2016.
The sponsorship was transferred Pharma Gateway AB, Sweden, in March 2019.
treatment of frontotemporal dementia with parkinsonism-17
|Orphan designation status||
|EU designation number||
|Date of designation||
Pharma Gateway AB
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: